Latest News

Despite recent inflationary pressures and concerns about consumer confidence, the Canadian S&P/TSX index has shown resilience, climbing 7.5% from its mid-March low. In such a fluctuating market, penny stocks—though an older term—remain a relevant investment area for those interested in smaller or newer companies with potential value. By focusing on firms with solid financial foundations, investors may uncover opportunities that offer both stability and growth potential.

On April 1, 2026, OGE Energy Corp. completed a registered US$350.0 million issuance of 5.90% Senior Notes due April 1, 2056, adding long-term capital to its balance sheet. This move, alongside strong recent earnings and positive analyst commentary, reinforces perceptions of OGE’s financial strength and capacity to fund ongoing infrastructure investments. Now we’ll examine how the new 30-year senior notes issuance interacts with OGE Energy’s earnings-driven investment narrative and future...

Dongfang Electric (SEHK:1072) has drawn fresh attention after reporting full year 2025 results alongside a declared final ordinary dividend of RMB 5.3 per 10 shares, providing both earnings and income updates for shareholders. See our latest analysis for Dongfang Electric. The full year results and higher dividend have arrived against a strong backdrop, with a 90 day share price return of 60.83% and a very large 1 year total shareholder return that far outpaces the short term moves. If...

Conference participation and recent achievements IRADIMED (IRMD) is in focus as it joins the 25th Annual Needham Virtual Healthcare Conference, where CFO John F. Glenn is scheduled for one on one investor meetings. The event follows record 2025 financials, dividend increases, and industry recognition, with added attention on how management presents priorities for growth, capital allocation, and ongoing investor outreach during the virtual sessions. See our latest analysis for IRADIMED. At a...

Over the last 7 days, the United States market has risen by 3.1%, contributing to a substantial 27% increase over the past year, with earnings forecasted to grow by 16% annually. In this context of robust growth, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on market dynamics and favorable economic conditions.

Over the last 7 days, the United States market has risen by 3.1%, contributing to a substantial 27% climb over the past year, with earnings forecasted to grow by 16% annually. In such a robust market environment, growth companies with high insider ownership can be particularly attractive as they often indicate strong confidence from those closest to the business operations and future prospects.

The market has shown robust performance, rising 3.1% over the last week and 27% over the past year, with earnings expected to grow by 16% annually in the coming years. In light of these conditions, identifying stocks with solid financials can be crucial for investors looking to capitalize on both value and growth opportunities. Penny stocks, despite their somewhat outdated moniker, remain relevant as they often represent smaller or newer companies that can offer significant potential when...

The United States market has been on an upward trajectory, climbing 3.1% in the past week and 27% over the last year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying stocks that combine strong fundamentals with growth potential can uncover promising opportunities for investors seeking to enhance their portfolios.

Over the last 7 days, the United States market has risen by 3.1%, contributing to a remarkable 27% increase over the past year, with earnings expected to grow by 16% annually in the coming years. In such a dynamic environment, reliable dividend stocks that offer attractive yields can provide investors with both income and potential growth opportunities.

Recent share performance and business snapshot Dr. Ing. h.c. F. Porsche (XTRA:P911) has attracted attention after a recent 1 day return of about 1.6%, adding to a roughly 9.7% move over the past month. Over the past 3 months, the stock shows a return of about a 5.6% decline, with year to date performance around a 14% decline and a 1 year total return close to a 2.5% decline, which gives investors a mixed recent picture. The company reports annual revenue of about €36.3b and net income of...

In Q4 2025, Xeris Biopharma reported record revenue growth and reached profitability, and guided for over 30% growth in both adjusted EBITDA and total revenue to between US$375 million and US$390 million for 2026, while also filing a patent infringement lawsuit to block generic versions of Recorlev until 2040. This combination of stronger financial performance and efforts to protect Recorlev’s market exclusivity could meaningfully influence expectations for the company’s future cash...

Why IQVIA’s recent moves are drawing fresh attention IQVIA Holdings (IQV) has been back in focus after launching its IQVIA.ai platform with NVIDIA, buying drug discovery assets from Charles River Laboratories, and teaming up with the Duke Clinical Research Institute. These moves, along with ongoing share buybacks and IQVIA’s top ranking on Fortune’s World’s Most Admired Companies list, are prompting investors to reassess how the stock’s current return profile lines up with its life sciences...

Karoon Energy recently reported quarterly revenue of A$326 million and net income of A$55 million from its oil and gas operations in Australia and Brazil, highlighting profitable production in the Santos, Carnarvon and Tumbes basins. Beyond the headline figures, the company’s active expansion plans in Brazil and Australia point to a concerted push to build out its production footprint and asset base. We’ll now examine how this strong quarterly profitability, underpinned by A$326 million in...

MDR certification puts eye cancer products in focus Eckert & Ziegler (XTRA:EUZ) has secured MDR certification for its ruthenium-106 eye applicators, a key regulatory milestone for continued European access to these isotope-based treatments for choroidal melanomas. See our latest analysis for Eckert & Ziegler. The MDR certification arrives as Eckert & Ziegler’s €14.62 share price shows mixed momentum, with a 1-day share price return of 1.74%, a 90-day share price return decline of 9.53%, a...

What the new Florida contract could mean for Webuild stock Webuild (BIT:WBD) is back in focus after its Lane subsidiary secured a US$582 million infrastructure contract in Florida, drawing attention to how these large project wins might feed into the group’s global construction pipeline. See our latest analysis for Webuild. The Florida win comes after a choppy period for the stock, with a 1-day share price return of 3.51% and 7-day share price return of 11.33%. This contrasts with a 90-day...

In March 2026, Li Auto reported delivering 41,053 vehicles, with cumulative deliveries reaching 1.64 million, and resolved production bottlenecks that allowed the Li i6 to exceed 24,000 monthly deliveries. The company paired this operational progress with the rollout of advanced autonomous driving technology, expanded ESG and climate reporting, and an ongoing share repurchase program, highlighting simultaneous execution across products, technology, sustainability, and capital...

DocuSign has integrated its Intelligent Agreement Management platform directly into Slack, allowing users to create, negotiate, and execute contracts inside Slack conversations. The integration focuses on keeping agreement workflows within the same channel where teams already communicate and collaborate. For investors tracking NasdaqGS:DOCU, this product update arrives after a period of weaker share performance. The stock last closed at $42.89, with returns of a 10.7% decline over the past...

Atour Lifestyle Holdings (ATAT) is back on traders’ radar after a fourth quarter earnings beat, a technical rating upgrade, and easing geopolitical tensions that have drawn investors toward travel and consumer names. See our latest analysis for Atour Lifestyle Holdings. At around $36.13, the stock has cooled after its recent rally, with a 30 day share price return of 2.53% against a weaker 90 day patch and a 1 year total shareholder return of 54.66%. This suggests that longer term momentum...

Inventiva (ENXTPA:IVA) is in focus after reporting full year 2025 earnings, with sales of €4.48 million, a net loss of €354.14 million and a basic loss per share from continuing operations of €1.9. See our latest analysis for Inventiva. The earnings release appears to have weighed on sentiment in the short term, with a 30 day share price return of 12.48% and a 90 day share price return of 7.65%, even as the year to date share price return is 11.87% and the 1 year total shareholder return is...

Central New Energy Holding Group (SEHK:1735) reported full year 2025 results, with sales of HK$11,016.85 million, net income of HK$34.24 million, and earnings per share of HK$0.0081 from continuing operations. See our latest analysis for Central New Energy Holding Group. The earnings release comes after a steady run in the shares, with a 9.55% 1 month share price return and 12.30% 3 month share price return. However, the 1 year total shareholder return is still down 6.58% while the 5 year...

In early April 2026, Roche announced that its Elecsys Neurofilament Light Chain (NfL) blood test received CE mark approval for detecting neuroinflammation in adults with relapsing-remitting multiple sclerosis, enabling minimally invasive monitoring via its widely installed cobas instruments. This approval could materially change multiple sclerosis care pathways by shifting more frequent disease monitoring from hospital-based MRI scans to accessible, standardized blood testing. Next, we’ll...

IperionX recently advanced its Virginia Titanium Manufacturing Campus, receiving the final US$4.6 million IBAS funding tranche and securing prototype orders from American Rheinmetall and Carver Pump to support commercialization of its high-purity titanium products. These developments mark a shift from technology claims to real-world execution, with investors now focusing on whether early prototype demand can translate into sustained, repeat production. Next, we’ll explore how the Virginia...

Earlier in April 2026, Ubiquiti reported quarterly results with earnings per share and revenue above analyst expectations, alongside recognition for strong profitability, financial health, and growth metrics. This combination of an earnings beat and third-party acknowledgement of quality and capital efficiency has sharpened investor focus on Ubiquiti’s underlying business strength. With this backdrop and Ubiquiti’s recent earnings beat, we’ll examine how the news reshapes the company’s...

In late March 2026, Teva Pharmaceutical Industries announced that the US FDA approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia, while regulators in the US and EU accepted the company’s applications for a biosimilar to Xolair (omalizumab), covering all currently approved indications for both reference products. These regulatory milestones mark a meaningful expansion of Teva’s biosimilar footprint in high-need areas such as osteoporosis and severe allergic disease, reinforcing its...